Efficacy and safety of sintilimab combined with chemotherapy in the treatment of stage Ⅲ to Ⅳ gastric/gastroesophageal junction adenocarcinoma
Objective To investigate the efficacy and safety of sintilimab in combination with chemotherapy for the first-line treatment of stage Ⅲ to Ⅳ gastric/gastroesophageal junction adenocarcinoma.Methods Patients with stage Ⅲ to Ⅳgastric/gastroesophageal junction adenocarcinoma admitted to the First Affiliated Hospital of Anhui Medical University from July 2020 to December 2023 were selected,and propensity score matching(PSM)analysis was used to include those who received sintilimab in combination with chemotherapy into the treatment group and those who received only chemotherapy into the control group.Treatment efficacy,overall survival(OS),and progression-free survival(PFS),as well as safety and tolerability were compared between the two groups.Results A total of 83 patients were included,with a median follow-up time of 16.9 months.30 patients were included in the treatment group and 53 in the control group,and 30 patients in both groups after PSM.After PSM,the PR ratio of the treatment group was higher than that of the control group,the clinical efficacy was better than that of the control group,and the ORR was higher than that of the control group with statistically significant differences(P<0.05).The median PFS and OS were 8.5(95%CI:7.0 to 10.3)months and 16.5(95%CI:12.8 to 19.6)months in the treatment group.The median PFS of the control group was 6.5(95%CI:4.2 to 7.1)months,and the median OS was 13.8(95%CI:10.5 to 16.9)months.The median PFS and median OS were longer in the treatment group than those in the control group,and the differences were statistically significant(P<0.05).For the total incidence of treatment-related adverse events and the incidence of grade 3 or higher adverse events,the differences between the two groups were not statistically significant(P>0.05).Conclusion First-line treatment with sintilimab combined with chemotherapy can improve PFS and OS in patients with stage Ⅲ to Ⅳ gastric/gastroesophageal junction adenocarcinoma and it is well tolerated.
万方数据
维普
